Pacylex Pharmaceuticals Inc.
Pacylex Pharmaceuticals is a clinical stage biotech company focused on developing first-in-class, oral cancer therapies targeting myristoylation. They are advancing a novel N-myristoyltransferase (NMT) inhibition therapy, zelenirstat, which has shown promising safety, efficacy, and biological activity across multiple cancer types, including solid tumors, lymphoma, and leukemia. The company is actively engaged in clinical trials, seeking partnerships and funding to expand its innovative cancer treatment portfolio.
Industries
Nr. of Employees
small (1-50)
Pacylex Pharmaceuticals Inc.
Products
Clinical‑stage oral N‑myristoylation inhibitor (investigational small molecule)
An orally administered small‑molecule inhibitor of protein myristoylation developed for oncology indications; characterized preclinically for tumor regression in hematologic and solid tumor models and advanced into Phase 1/2a clinical studies.
Clinical‑stage oral N‑myristoylation inhibitor (investigational small molecule)
An orally administered small‑molecule inhibitor of protein myristoylation developed for oncology indications; characterized preclinically for tumor regression in hematologic and solid tumor models and advanced into Phase 1/2a clinical studies.
Services
Early-phase oncology clinical development
Design and execution of Phase 1 dose-escalation studies and Phase 2a expansion cohorts for investigational oral oncology agents, including multi-site enrollment, safety monitoring, and PK/PD assessments.
Preclinical translational research and biomarker development
Execution of in vitro, ex vivo and in vivo studies to characterize efficacy, mechanism-of-action, and predictive biomarkers, including development of gene-expression sensitivity signatures.
Regulatory strategy and submission support
Preparation and management of regulatory filings and interactions including IND submissions and pursuit of Orphan Drug and accelerated/expedited pathways.
Early-phase oncology clinical development
Design and execution of Phase 1 dose-escalation studies and Phase 2a expansion cohorts for investigational oral oncology agents, including multi-site enrollment, safety monitoring, and PK/PD assessments.
Preclinical translational research and biomarker development
Execution of in vitro, ex vivo and in vivo studies to characterize efficacy, mechanism-of-action, and predictive biomarkers, including development of gene-expression sensitivity signatures.
Regulatory strategy and submission support
Preparation and management of regulatory filings and interactions including IND submissions and pursuit of Orphan Drug and accelerated/expedited pathways.
Expertise Areas
- Clinical trial management (Phase 1/Phase 2a)
- Targeted small‑molecule oncology drug development
- Biomarker discovery and predictive signatures
- Translational preclinical models and PDX/ex vivo testing
Key Technologies
- Myristoylation (N‑myristoyltransferase) inhibition
- Oral small‑molecule therapeutics
- Gene expression–based sensitivity signatures
- In vitro cytotoxicity and ex vivo patient tissue assays